Trials / Completed
CompletedNCT03058406
A Study on Safety and Efficacy in Patients With Soft Tissue Sarcomas
Special Use Investigation of HALAVEN (HAL03T) - Study on Safety and Efficacy in Patients With Soft Tissue Sarcomas
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 256 (actual)
- Sponsor
- Eisai Co., Ltd. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to understand safety and efficacy in participants with soft tissue sarcomas.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Eribulin mesylate | Participants will receive 1.4 milligrams per square meter (mg/m2) administered as an intravenous (IV) infusion (over 2 to 5 minutes) on Days 1 and 8 of each 3-week cycle and beyond. |
Timeline
- Start date
- 2016-03-01
- Primary completion
- 2018-11-04
- Completion
- 2018-11-04
- First posted
- 2017-02-20
- Last updated
- 2020-04-06
Locations
2 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT03058406. Inclusion in this directory is not an endorsement.